C2N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood-Based Biomarkers in the Diagnosis of Alzheimer’s Disease
ST. LOUIS--(BUSINESS WIRE)-- #Alzheimers--C2N Diagnostics, LLC (“C2N”) provided today a recap of the multiple presentations at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, November 29 – December 2, 2022, in San Francisco, highlighting the clinical utility and performance of the company’s blood-based biomarkers for the evaluation of patients...
